Qingdao NovelBeam Technology Co.,Ltd. (SHA:688677)
China
· Delayed Price · Currency is CNY 111.00
-11.66 (-9.51%)
Apr 29, 2026, 3:00 PM CST
SHA:688677 Revenue
Qingdao NovelBeam Technology had revenue of 174.46M CNY in the quarter ending March 31, 2026, with 18.77% growth. This brings the company's revenue in the last twelve months to 630.18M, up 33.49% year-over-year. In the year 2025, Qingdao NovelBeam Technology had annual revenue of 602.61M with 36.08% growth.
Revenue (ttm)
630.18M
Revenue Growth
+33.49%
P/S Ratio
23.06
Revenue / Employee
749.33K
Employees
967
Market Cap
14.53B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 602.61M | 159.78M | 36.08% |
| Dec 31, 2024 | 442.83M | -27.77M | -5.90% |
| Dec 31, 2023 | 470.60M | -6.22M | -1.31% |
| Dec 31, 2022 | 476.82M | 167.15M | 53.97% |
| Dec 31, 2021 | 309.67M | 34.48M | 12.53% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Micro-Tech (Nanjing) Co.,Ltd | 3.19B |
| Jiangsu Hualan New Pharmaceutical Material | 604.86M |
| Autek China | 1.84B |
| Shenyang Xingqi Pharmaceutical | 2.47B |
| Winner Medical | 11.02B |
| Tofflon Science and Technology Group | 5.22B |
| Eyebright Medical Technology (Beijing) | 1.52B |
| Sansure Biotech | 1.65B |